Rafiq M, Rehman M, Rasool J, Ahmad I.
Treatment of Diabetic Macular Oedema with Intravitreal Bevacizumab (Avastin) (A Current Approach).
Ophthalmol Update Jan ;15(2):74-6.

Purpose of the study: To see anatomic and visual outcomes after treatment of diffuse diabetic macular edema intravitreal bevacizumab (Avastin). Study Design: Prospective case series study. Materials and Methods: In this study, we included 20 eyes of patients from outpatient department (OPD) of ophthalmology in Rehman Medical Institute who had controlled diabetes mellitus (DM) with diffuse diabetic macular edema with a mean age of 65 years. They were treated with three intravitreal injections of bevacizumab 1.25 mg in 0.05 ml, 01 month apart. Outcome was measured mainly in terms of visual acuity (VA) and central macular thickness seen with optical coherence tomography imaging. Patients were examined at baseline and follow-up visits. Results: All the patients in the study received three injections of intravitreal bevacizumab with an interval of one month per eye. No complication like endophthalmitis, inflammation and increased intraocular pressure or thromboembolic event occurred in any patient. In our study, the mean baseline acuity was measured as 20/494 (log Mar=1.338�0.455) and the mean acuity at three months follow up turned out to be 20/295 (log Mar=1.094�0.254) which was highly significant (P =0.008). In the same manner, mean central macular thickness decreased to 369 �m at three months from 492 �m at baseline ( P =0.001) . Conclusion: Intravitreal bevacizumab resulted in a significant improvement in visual acuity and decrease in macular oedema in diabetic patients at three months. Though effect was reduced at 06 months interval but still significant statistically.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com